ClearPoint Neuro, Inc. filed a Form D with the Securities and Exchange Commission on 2026-02-05.
ClearPoint Neuro, Inc. filed a Form D notice of an exempt securities offering with the SEC on February 5, 2026. The filing reports $17.89M sold. Its industry group is Biotechnology. It names Joseph Burnett (Executive Officer, Director), R. Fletcher (Director), Lynnette Fallon (Director) (SEC Form D, February 5, 2026).
Sell to companies like ClearPoint Neuro, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-02-05 · the record
Pitching, partnering or investing alongside them? See who really runs and owns ClearPoint Neuro, Inc.
Free to see. No signup.
More on the people and the money behind ClearPoint Neuro, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in February 2026, largest first.
Get an email when ClearPoint Neuro, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when ClearPoint Neuro, Inc. raises, hires or launches. No email unless you switch it on.
Watch ClearPoint Neuro, Inc. →Get the full cited report on ClearPoint Neuro, Inc.
What the filing shows about ClearPoint Neuro, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on ClearPoint Neuro, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $17.89M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Joseph Burnett is named as Executive Officer and Director on the Form D that ClearPoint Neuro, Inc. filed with the SEC on 5 February 2026, one of 11 people that filing names.
R. Fletcher is named as Director on the Form D that ClearPoint Neuro, Inc. filed with the SEC on 5 February 2026, one of 11 people that filing names.
Lynnette Fallon is named as Director on the Form D that ClearPoint Neuro, Inc. filed with the SEC on 5 February 2026, one of 11 people that filing names.
Pascal Girin is named as Director on the Form D that ClearPoint Neuro, Inc. filed with the SEC on 5 February 2026, one of 11 people that filing names.
B. Johnson is named as Director on the Form D that ClearPoint Neuro, Inc. filed with the SEC on 5 February 2026, one of 11 people that filing names.
Matthew Klein is named as Director on the Form D that ClearPoint Neuro, Inc. filed with the SEC on 5 February 2026, one of 11 people that filing names.
Linda Liau is named as Director on the Form D that ClearPoint Neuro, Inc. filed with the SEC on 5 February 2026, one of 11 people that filing names.
Timothy Richards is named as Director on the Form D that ClearPoint Neuro, Inc. filed with the SEC on 5 February 2026, one of 11 people that filing names.
Danilo D'Alessandro is named as Executive Officer on the Form D that ClearPoint Neuro, Inc. filed with the SEC on 5 February 2026, one of 11 people that filing names.
Jeremy Stigall is named as Executive Officer on the Form D that ClearPoint Neuro, Inc. filed with the SEC on 5 February 2026, one of 11 people that filing names.
Mazin Sabra is named as Executive Officer on the Form D that ClearPoint Neuro, Inc. filed with the SEC on 5 February 2026, one of 11 people that filing names.
11 people named on the filing — 4 holding an executive role and 7 as directors only.
Named as of the 2026-02-05 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about ClearPoint Neuro, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on ClearPoint Neuro, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ClearPoint Neuro, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist ClearPoint Neuro, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind ClearPoint Neuro, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for ClearPoint Neuro, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Diego
https://mentionfox.com/funding/clearpoint-neuro-inc-form-d-26000001